Stakeholders urge FDA to strengthen guidance on biosimilars promotions, stop bad actors
Regulatory NewsEmily Hayes
Advertising, Promotion and LabelingBiologics/ biosimilars/ vaccinesGuidanceUnited StatesUS Food and Drug Administration (FDA)Regulatory NewsEmily HayesAdvertising, Promotion and LabelingBiologics/ biosimilars/ vaccinesGuidanceUnited StatesUS Food and Drug Administration (FDA)